Orthofix Medical (OFIX) Q2 2024 earnings summary

Executive summary

• Q2 2024 net sales reached $198.6 million, up 6% year-over-year, driven by strong growth in Bone Growth Therapies and U.S. Spine Fixation, and supported by expanding product portfolio and leadership changes.

• Integration of the SeaSpine merger continues, with realized synergies and operational milestones, including ERP implementation and leadership appointments.

• Cash usage improved significantly, positioning for positive free cash flow in the second half of 2024, ahead of prior expectations.

• Leadership team finalized and strengthened, focusing on profitable growth, strategic innovation, and cross-functional initiatives.

Financial highlights

• Q2 2024 net sales: $198.6M (+6% year-over-year); adjusted EBITDA: $16.6M (8.4% margin), with a 310 basis point margin expansion over Q2 2023.

• Gross margin: 67.8% (GAAP), 71.3% (non-GAAP adjusted) for Q2 2024.

• Adjusted net income for Q2 2024 was $1.7 million, up from $0.7 million in Q2 2023.

• Cash, cash equivalents, and restricted cash totaled $28.9 million at June 30, 2024.

• Q2 2024 net loss was $33.4M, or $(0.88) per share, an 18% improvement from Q2 2023.

Outlook and guidance

• Full-year 2024 net sales guidance raised to $795–800 million (6.7%–7.4% growth), and adjusted EBITDA guidance increased to $64–69 million.

• Company expects to achieve positive free cash flow in the second half of 2024, earlier than previously anticipated.

• Full-year gross margin expected to be around 71%, with operating expenses decreasing 200–300 basis points.